Key driver of aggressive prostate cancer identified, suggesting new way to reverse drug resistance

Key Points:

• Researchers at Fred Hutch Cancer Center discovered that a specific transfer RNA (tRNA1Arg(UCU)) plays a crucial role in determining whether prostate cancer cells remain sensitive to treatment or become aggressive and drug-resistant.
• The study, published in Nature, shows that this single tRNA can shift prostate cancer cells between androgen receptor–dependent (treatment-sensitive) and androgen receptor–independent (treatment-resistant) states, influencing tumor behavior and therapy response.
• This finding challenges the traditional view of tRNAs as mere bystanders, revealing their active role in shaping cancer cell identity and disease progression.
• The researchers suggest that this mechanism may apply to other cancers that undergo identity changes after treatment, such as lung and breast cancers, and are exploring the potential of tRNA as a biomarker or therapeutic target for aggressive prostate cancer.
• The study opens new avenues for understanding cancer biology and developing more precise treatments by targeting molecular regulators beyond genomic mutations and gene expression.